Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
Hudgens S, Floden L, Blackowicz M, Jamieson C, Popova V, Fedgchin M, Drevets WC, Cooper K, Lane R, Singh J.
J Affect Disord. 2021 Feb 15;281:767-775. doi: 10.1016/j.jad.2020.11.066. Epub 2020 Nov 14.
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E.
N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443.
Bifidobacterium breve CCFM1025 attenuates major depression disorder via regulating gut microbiome and tryptophan metabolism: A randomized clinical trial.
Tian P, Chen Y, Zhu H, Wang L, Qian X, Zou R, Zhao J, Zhang H, Qian L, Wang Q, Wang G, Chen W.
Brain Behav Immun. 2022 Feb;100:233-241. doi: 10.1016/j.bbi.2021.11.023. Epub 2021 Dec 4.
Validation of Bangla Montgomery Asberg Depression Rating Scale (MADRSB).
Soron TR.
Asian J Psychiatr. 2017 Aug;28:41-46. doi: 10.1016/j.ajp.2017.03.019. Epub 2017 Mar 22.
Montgomery-Asberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Borentain S, Gogate J, Williamson D, Carmody T, Trivedi M, Jamieson C, Cabrera P, Popova V, Wajs E, DiBernardo A, Daly EJ.
Int J Methods Psychiatr Res. 2022 Dec;31(4):e1927. doi: 10.1002/mpr.1927. Epub 2022 Jun 24.
Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M, Blier P.
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:54-63. doi: 10.1016/j.pnpbp.2013.04.009. Epub 2013 Apr 19.
Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Asberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
Kern Sliwa J, Naranjo RR Jr, Turkoz I, Petrillo MP, Cabrera P, Trivedi M.
CNS Spectr. 2024 Jun;29(3):176-186. doi: 10.1017/S1092852924000105. Epub 2024 Apr 1.
A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression.
Zimmerman M, Chelminski I, Posternak M.
Int Clin Psychopharmacol. 2004 Jan;19(1):1-7. doi: 10.1097/00004850-200401000-00001.
Reliability and validity of the telephone-based version of the Montgomery-Asberg depression rating scale for assessing depression in individuals with primary brain tumour.
Harris G, Jones S, Pinkham MB, Lion KM, Ownsworth T.
Disabil Rehabil. 2024 Mar;46(6):1158-1166. doi: 10.1080/09638288.2023.2191015. Epub 2023 Apr 5.
Validation of Montgomery-Asberg Rating Scale and Cornell Scale for Depression in Dementia in Brazilian elderly patients.
Portugal Mda G, Coutinho ES, Almeida C, Barca ML, Knapskog AB, Engedal K, Laks J.
Int Psychogeriatr. 2012 Aug;24(8):1291-8. doi: 10.1017/S1041610211002250. Epub 2011 Dec 20.
